

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-28. Canceled
29. (Currently amended) A monomeric soluble form of a member of the CD83 family of proteins (monomeric CD83 protein)[[.]] selected from the group consisting of a soluble CD83 protein consisting of amino acid residues 20 to 145 of SEQ ID NO:2 and a soluble CD83 protein consisting of amino acid residues 1 to 130 of SEQ ID NO:8; wherein one or more cysteine residues are substituted with a small and/or polar amino acid residue.
30. (Previously presented) The monomeric CD83 protein of claim 29, wherein one or more cysteine residues are substituted with an amino acid residue selected from the group consisting of serine, alanine, glycine, valine, threonine, lysine, arginine, glutamine, asparagine, glutamate and aspartate.
31. (Previously presented) The monomeric CD83 protein of claim 30, wherein one or more cysteine residues are substituted with serine.
32. (Previously presented) The monomeric CD83 protein of claim 29, wherein the C-terminus of said protein comprises one or more amino acid residues derived from the neighboring intracellular domain.

33. (Currently amended) The monomer CD83 protein of claim 32, wherein said soluble protein [[comprises]] consists of amino acid residue 20 to 145 of SEQ ID NO:2, and wherein one or more cysteine residues are substituted with a small and/or polar amino acid residue.
34. (Canceled)
35. (Currently amended) The monomeric CD83 protein of claim 29, which [[comprises]] consists of amino acid residues 1 to 130 of SEQ ID NO:8, and wherein one or more cysteine residues are substituted with a small and/or polar amino acid residue.
36. (Previously presented) The monomeric CD83 protein of claim 29, wherein one cysteine residue has been substituted.
37. (Currently amended) The monomeric CD83 protein of claim 29, wherein more than one cysteine residue has been substituted.
38. (Previously presented) The monomeric CD83 protein of claim 36, wherein the fifth cysteine residue is substituted.
39. (Currently amended) The monomeric soluble CD83 protein of claim 29, which [[comprises]] consists of amino acid residues 1 to 130 of SEQ ID NO:10.

40-45 (Canceled)

46. (Previously presented) A pharmaceutical composition comprising the monomeric CD83 protein of claim 29.

47-48. (Canceled)

49 (Previously Presented) A method for treating or preventing a disease or medical condition caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells, comprising administering to the a person in need of such treatment a pharmaceutically suitable amount of the monomeric CD83 protein of claim 29.

50. (Previously Presented) The method of claim 49, wherein said disease or medical condition is selected from the group consisting of allergies, asthma, rejection of a tissue or organ transplanted, autoimmune syndromes such as myasthenia gravis, multiple sclerosis, vasculitis, chronic inflammatory bowel disease, Morbus Crohn, colitis ulcerosas, HLA B27-associated autoimmunopathis, Morbus Bechterew, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, insulin-dependent diabetes mellitus and AIDS.

51. (Previously Presented) The method of claim 50, wherein said disease is multiple sclerosis.
52. (Canceled)
53. (New) A monomeric soluble form of a member of the CD83 family of proteins (monomeric CD83 protein) selected from the group consisting of a soluble CD83 protein consisting of amino acid residues 20 to 145 of SEQ ID NO:2 and a soluble CD83 protein consisting of amino acid residues 1 to 130 of SEQ ID NO:8, each having the additional amino acid residues Gly-Ser-Pro-Gly at the N-terminus; wherein one or more cysteine residues are substituted with a small and/or polar amino acid residue.